NEULANDLAB - Neuland Laboratories

Neuland Laboratories

NEULANDLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Davuluri Rama Mohan Rao · MD: Davuluri Saharsh Rao · Listing date: Oct. 14, 2008 · Employees: 1427 · Hyderabad · http://www.neulandlabs.com

Stock Price vs Company Growth

4.8%

4.1%

5.0%

41.9%

90.7%

66.3%

70.3%

10y

37.8%

all

36.8%

🤔 How to analyze this graph?

Last Traded Price

₹ 23,975 4.8%

16,539

24,043

Company Overview

Sales

2,372 Cr

Growth: 42.6%

Profit after Tax

498 Cr

Growth: 36.8%

Large Cap

30,760 Cr

P/E: 61.5x

Industry P/E: 34.2x

Fundamentals

Sales (Cr)	₹ 2,372
Growth	42.6%
EBITDA	32.2%
P/S	12.9x
Dividend	0.1%
P/E	61.5x
Book Value	₹ 1,575
PEG Ratio	1.4x
ROE	27.6%
P/B	14.4x

Shareholding Pattern

Institutions

Malabar India Fund Limited

9.95 %

Malabar Value Fund

4.29 %

Matthews India Fund

2.55 %

Icg Q Limited

1.76 %

Promoters

Ramamohan Rao Davuluri

24.97 %

Davuluri Vijaya Rao

4.78 %

Davuluri Sucheth Rao

2.63 %

Davuluri Saharsh Rao

1.98 %

Davuluri Rohini Niveditha Rao

1.27 %

Others

Mukul Mahavir Agrawal

2.34 %

Kedia Securities Private Limited

1.01 %

Iepf

0.21 %

Increase Decrease No change

Company Profile Detailed

The company is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.Business verticalsGeneric drug substances (GDS): Manufacturing of generic, non-exclusive complex APIs.Custom manufacturing solutions (CMS): Contract development and manufacturing of NCE APIs and advanced intermediates for innovators.

Belongs to (31 Indices) view more

Investors (94)

dolly.kh...

icici.pr...

siddhart...

Followers (2)

harit

nilofer4